A multicenter, randomized, double-blind, double-dummy, positive-controlled study of the general treatment method using Tanreqing capsule (痰热清胶囊) in uncomplicated influenza

doi:10.19852/j.cnki.jtcm.2026.05.018

Journal of Traditional Chinese Medicine ›› 2026, Vol. 46 ›› Issue (5): 1257-1265.DOI: 10.19852/j.cnki.jtcm.2026.05.018

• Original Articles • Previous Articles Next Articles

A multicenter, randomized, double-blind, double-dummy, positive-controlled study of the general treatment method using Tanreqing capsule (痰热清胶囊) in uncomplicated influenza

SU Rui¹, SU Youzhu², SUN Hongyuan³, WU Caijun⁴, QI Wensheng⁵, ZHANG Lei⁶, LIU Qingquan¹(), WANG Shuo¹()

¹ Department of Infectious Diseases, Beijing Traditional Chinese Medicine Hospital, Capital Medical University, Beijing 100010, China
² Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China
³ Department of Infectious Diseases, the First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300380, China
⁴ Emergency Department of Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine, Beijing 100700, China
⁵ Emergency Department of Guang'anmen Hospital, Chinese Academy of Traditional Chinese Medicine, Beijing 100053, China
⁶ Emergency Department of Yanqing District Traditional Chinese Medicine Hospital, Beijing 102100, China

Received:2025-03-28 Accepted:2026-01-09 Online:2026-10-15 Published:2026-10-09
Contact: Prof. LIU Qingquan, Department of Infectious Diseases, Beijing Traditional Chinese Medicine Hospital, Capital Medical University, Beijing 100010, China. liuqingquan2003@126.com,Telephone: +86-10-87906813; Prof. WANG Shuo, Department of Infectious Diseases, Beijing Traditional Chinese Medicine Hospital, Capital Medical University, Beijing 100010, China. ysys2001@yeah.net, Telephone: +86-10-87906520
About author:
SU Rui and SU Youzhu are co-first authors and contributed equally to this work
Supported by:
National Key Research and Development Plan: Study on the Rule of Diagnosis and Treatment of Traditional Chinese Medicine for Coronavirus Disease 2019 Infection and Optimization of the Scheme(2021yfc1712901)

Abstract

Abstract:

OBJECTIVE: To investigate the effects of the method of clearing heat, resolving phlegm, and detoxification, represented by Tanreqing capsule (TRQC, 痰热清胶囊), on influenza.

METHODS: A total of 122 patients with uncomplicated influenza in the Beijing-Tianjin area were randomly divided into an observation group and a control group. They were treated with TRQC plus oseltamivir placebo or oseltamivir plus TRQC placebo for 5 d, respectively. The relief time for influenza symptoms, individual symptom relief time, the frequency of antipyretic drug usage, and the frequency of antibiotic drug usage were analyzed.

RESULTS: External wind-cold syndrome (28.69%) and external wind-heat syndrome (45.08%) were the most common syndrome types. The number of patients in TRQC group achieved normal temperature within 1 d was significantly more than oseltamivir group (72.88% vs50.80%, P < 0.05). There were no significant differences in the time for influenza symptom relief and individual symptom relief between the two groups. TRQC showed a better heat relief effect than oseltamivir on the fifth day of treatment.

CONCLUSION: TRQC, as a "Tongzhi" method (General treatment), has a curative effect on uncomplicated influenza that is similar to oseltamivir, with a better effect on prolonged fever. TRQC is an effective method of general treatment for influenza and can serve as an alternative therapy for managing large-scale influenza epidemics.

Key words: influenza, general treatment, efficacy evaluation, randomized controlled trial

SU Rui, SU Youzhu, SUN Hongyuan, WU Caijun, QI Wensheng, ZHANG Lei, LIU Qingquan, WANG Shuo. A multicenter, randomized, double-blind, double-dummy, positive-controlled study of the general treatment method using Tanreqing capsule (痰热清胶囊) in uncomplicated influenza[J]. Journal of Traditional Chinese Medicine, 2026, 46(5): 1257-1265.

Figures/Tables 7

References 24

[1]	Erik D. Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 2006; 5: 1015-25.
[2]	China Association of Chinese Medicine. Tong Xiaolin: The "Wuchang Model" of Traditional Chinese Medicine provides new ideas for community epidemic prevention and control. Zhong Yi Lin Chuang Yan Jiu 2020; 12: 6.
[3]	Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemoth 2003 51: 123-9.
[4]	Collins P J, Haire LF, Lin YP, et al. Structural basis for oseltamivir resistance of influenza viruses. Vaccine 2009; 27: 6317-23.
[5]	Petrosillo N, Di BS, Drapeau CM, Grilli E. The novel influenza A (H1N1) virus pandemic: an update. Ann Thorac Medi 2009; 4: 163.
[6]	XU Y, Zhong PP, Tao YY. Metabolic profiling of endogenous bile acids: a novel method to assess hepatoprotective effect of Tanreqing capsule on carbontetrachloride-induced liver injury in rats. Chin J Nat Med 2018; 16: 271-83.
[7]	He YQ, Zhao Y, Ma Y, et al. Research progress on chemical composition, pharmacological effects, and clinical applications of Tanre Qing capsule. Zhng Guo Yao Fang 2021; 32: 1639-47.
[8]	National Health Commission of the People's Republic of China. Influenza diagnosis and treatment program (2020 revision). Zhong Hua Lin Chuang Gan Ran Bing Za Zhi 2020; 13: 401-5.
[9]	John J, Frederick G, Peter S, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000; 283: 1016-24.
[10]	Nicholson KG, Aoki FY, Osterhaus A, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 2000; 355: 1845-50.
[11]	Monto A, Gravenstein S, Elliott M, Colopy I, Schweinle M. Clinical signs and symptoms predicting influenza infection. Ach Intern Med 2000; 21: 3243-7.
[12]	Wang T, Han LF, Wang YF, et al. Research progress of traditional Chinese patent medicines and simple preparations in the treatment of viral pneumonia. J Tradit Chin Med 2020; 45: 1509-14.
[13]	Su R, Liu QQ. Prospective non-randomized controlled study of Tuire Formula in the treatment of influenza based on the theory of ‘cold and heat syndrome differentiation combination. Zhong Yi Za Zhi 2020; 37: 1509-14.
[14]	Su R, Liu QQ. The relationship between influenza and typhoid and febrile diseases. Zhong Yi Za Zhi 2019; 60: 1249-51.
[15]	Song B, Lei Y, Zhao LH, et al. Application of “Universal Formula”in the prevention and treatment of COVID-19 and its innovative development. Zhong Guo Xin Yao Za Zhi 2020; 16: 1807-12.
[16]	Tong XL, LI XY, Zhao LH, et al. Discussion on Traditional Chinese Medicine prevention and treatment strategies of Coronavirus Disease 2019 (COVID-19) from the Perspective of “Cold-dampness Pestilence”. Zhong Yi Za Zhi 2020; 61: 465-70.
[17]	Zhang LL, Li Z, Xu XY, et al. The main pharmacodynamic study of Tanreqing capsules. Zhong Guo Shi Yan Fang Ji 2004; 10: 37-40.
[18]	Fan XH, Fan JM, Bi QL, Mao B, Tian ZJ. A randomized, double-blind, single simulated, multicenter clinical study (Phase III) on the treatment of acute tracheobronchitis (wind heat attacking lung syndrome) with Tanreqing capsules. Zhong Yao Yao Li Yu Lin Chuang 2020; 36: 238-41.
[19]	Zhang XY. The effect of Tanreqing capsule combined with antibiotics on serum hs CRP and procalcitonin levels in elderly patients with acquired pneumonia. Shanxi Zhong Yi 2015; 36: 1590-1.
[20]	Guo LY, Wei SH, Dong YM, et al. The efficacy and safety of Tanreqing capsule combined with hormone antibiotics in the treatment of radiation pneumonia. Zhong Hua Zhong Yi Yao Xue Kan 2020; 38: 218-21.
[21]	Lin RY, Zhang X, Zhang S, Zhang HX. Clinical study on Tanreqing capsules combined with umebromide veranterol in the treatment of stable acute attack of chronic obstructive pulmonary disease. Xian Dai Yao Wu Yu Lin Chuang 2022; 37: 1769-73.
[22]	Zhang L, Liu XQ, Lu YR, etal. Study on disease names of 934 cases of influenza A (H3N2) subtype influenza in Beijing. Shi Jie Zhong Yi Yao 2018; 13: 290-4.
[23]	Zhang W, Wang YG, Liu QQ, et al. TCM Syndromes and etiology-pathogenesis of severe and critical cases of influenza A (H1N1): an analysis of 123 cases. Zhong Yi Za Zhi 2011; 52: 35-8.
[24]	Ninomiya K, Madenokouji N, Hajikano M, Kawabata K, Matsuoka K, Fukunaga Y. Frequency and effects of bacterial infection in children with influenza under oseltamivir treatment. J Nippon Med Sch 2006; 73: 122-8.

Item	TRQC (n = 59)	Oseltamivir (n = 63)	P value
Male [n (%)]	34 (57.6)	37 (58.7)	0.4
Female [n (%)]	25 (42.8)	26 (41.3)	0.4
Age (years)	33.0±17.7	34.3±14.6	0.95
Weight (kg)	60.8±17.1	66.6±14.0	0.06
Temperature (°C)	38.5±0.7	38.4-±0.6	0.54
Heart rate (bpm)	90.7±15.3	90.7±14.6	0.99
Systolic blood pressure (mm Hg)	122.3±9.6	120.0±9.6	0.19
Diastolic blood pressure (mm Hg)	79.8±6.6	77.4±11.4	0.24
Type A (%)	25 (42.4)	24 (38.1)	0.98
Type B (%)	3 (5.1)	3 ( 4.8)	0.98
Unclassified (%)	31 (52.5)	36(57.1)	0.98
White blood cells (10¹²/L)	7.0±2.3	8.3±4.2	0.14
Neutrophils (%)	68.4±18.4	69.9±10.7	0.98
Lymphocytes (×10⁹/L)	17.2±8.3	18.1±8.0	0.96
Red blood cells (×10⁹/L)	4.8±0.4	5.1±0.4	0.10
Hemoglobin (g/L)	147.6±11.8	155.6±12.7	0.58
Platelets (×10⁹/L)	197.1±47.7	210.9±46.3	0.49
ALT (μ/L)	20.2±13.3	40.1±42.0	0.27
AST (μ/L)	19.3±5.3	30.4±23.4	0.07
BUN (μ/L)	3.5±1.1	4.5±1.7	0.20
Cr (μmol/L)	57.6±22.4	62.3±12.8	0.62

Item	TRQC (n = 59)	Oseltamivir (n = 63)	P value
Male [n (%)]	34 (57.6)	37 (58.7)	0.4
Female [n (%)]	25 (42.8)	26 (41.3)	0.4
Age (years)	33.0±17.7	34.3±14.6	0.95
Weight (kg)	60.8±17.1	66.6±14.0	0.06
Temperature (°C)	38.5±0.7	38.4-±0.6	0.54
Heart rate (bpm)	90.7±15.3	90.7±14.6	0.99
Systolic blood pressure (mm Hg)	122.3±9.6	120.0±9.6	0.19
Diastolic blood pressure (mm Hg)	79.8±6.6	77.4±11.4	0.24
Type A (%)	25 (42.4)	24 (38.1)	0.98
Type B (%)	3 (5.1)	3 ( 4.8)	0.98
Unclassified (%)	31 (52.5)	36(57.1)	0.98
White blood cells (10¹²/L)	7.0±2.3	8.3±4.2	0.14
Neutrophils (%)	68.4±18.4	69.9±10.7	0.98
Lymphocytes (×10⁹/L)	17.2±8.3	18.1±8.0	0.96
Red blood cells (×10⁹/L)	4.8±0.4	5.1±0.4	0.10
Hemoglobin (g/L)	147.6±11.8	155.6±12.7	0.58
Platelets (×10⁹/L)	197.1±47.7	210.9±46.3	0.49
ALT (μ/L)	20.2±13.3	40.1±42.0	0.27
AST (μ/L)	19.3±5.3	30.4±23.4	0.07
BUN (μ/L)	3.5±1.1	4.5±1.7	0.20
Cr (μmol/L)	57.6±22.4	62.3±12.8	0.62

Visit symptom		TRQC (n = 59)	Oseltamivir (n = 63)	Total (n = 122)
Fever	37.4-38 ℃	15 (25.42)	14 (22.22)	29 (23.78)
	38-39 ℃	31 (52.54)	40 (63.49)	71 (58.20)
	39-40 ℃	13 (22.03)	9 (14.29)	22 (18.03)
Aversion to cold		42 (71.19)	44 (69.84)	86 (70.49)
Sweating		19 (32.20)	26 (41.27)	45 (36.89)
Cough		44 (74.58)	51 (80.10)	95 (77.87)
	Mild	17 (28.81)	21 (33.33)	38 (31.15)
	Moderate	22 (37.29)	27 (42.86)	49 (40.16)
	Severe	5 (8.47)	3 (4.76)	8 (6.56)
Expectoration	Non	25 (42.37)	29 (46.03)	54 (44.26)
	less	29 (49.15)	28 (44.44)	57 (46.72)
	Much	5 (8.47)	6 (9.52)	11 (9.02)
	White	23 (39.00)	21 (33.33)	44 (36.06)
	Yellow	11 (18.64)	13 (20.63)	24 (19.67)
	Viscous	18 (30.51)	24 (38.10)	42 (24.43)
	Clear	16 (27.12)	10 (15.87)	26 (21.31)
Runny nose		29 (49.15)	29 (46.03)	58 (47.54)
	Clear	24 (40.68)	23 (36.51)	47 (38.52)
	Yellow	5 (8.47)	6 (9.52)	11 (9.02)
Nasal obstruction Obstruction		21 (25.59)	35 (55.56)	56 (45.90)
Sore throat		44 (74.58)	41 (65.08)	85 (69.67)
	Mild	20 (33.90)	16 (25.40)	36 (29.51)
	Moderate	19 (32.20)	22 (34.92)	41 (33.61)
	Severe	5 (8.47)	3 (4.76)	8 (6.56)
Dry mouth		30 (50.85)	31 (49.21)	61 (50.00)
Myalgia		37 (62.71)	43 (68.25)	80 (65.57)
	Mild	16 (27.12)	18 (28.57)	34 (27.87)
	Moderate	14 (23.73)	16 (25.40)	30 (24.59)
	Severe	7 (11.86)	9 (14.29)	16 (13.11)
Headache		44 (74.58)	53 (84.13)	95 (79.51)
	Mild	24 (40.68)	22 (34.92)	34 (27.87)
	Moderate	14 (23.73)	23 (36.51)	30 (24.59)
	Severe	6 (10.17)	8 (12.70)	16 (13.11)
Chest pain		13 (22.03)	10 (15.87)	23 (18.85)
Fatigue		46 (77.97)	49 (77.78)	95 (77.87)
Insomnia		8 (13.56)	9 (14.29)	17 (13.93)
Constipation		9 (15.25)	6 (9.52)	15 (12.30)
Ungratifying defecation		1 (1.69)	5 (7.94)	6 (4.92)
Loose stool		6 (10.17)	4 (6.35)	15 (12.30)
Anorexia		26 (44.07)	28 (44.44)	54 (44.26)
Vomit		8 (13.56)	3 (4.76)	11 (9.02)
Yellow urine		23 (39.00)	24 (38.10)	47 (38.52)
Clear urine		31 (52.54)	30 (47.62)	61 (50.00)
Tongue shape	Old	6 (10.17)	3 (4.76)	9 (7.38)
	Tender	21 (35.59)	22 (34.82)	43 (35.25)
	Bulky	15 (25.42)	17 (27.00)	32 (26.23)
	Thin	10 (16.95)	9 (14.29)	19 (15.57)
	Crack	4 (6.78)	10 (15.87)	14 (11.48)
	Others	3 (5.08)	2 (3.17)	5 (4.10)
Tongue color	Pale white	12 (20.33)	15 (23.81)	27 (22.13)
	Light red	23 (38.98)	31 (49.21)	54 (44.26)
	Red	24 (40.68)	17 (26.98)	41 (33.61)
Tongue coating	Thick	14 (23.73)	13 (20.63)	27 (22.13)
	Thin	25 (42.37)	27 (42.86)	52 (42.62)
	moist	2 (3.39)	2 (3.17)	4 (3.28)
	dryness	2 (3.39)	1 (1.59)	3 (2.46)
	Greasy	15 (25.42)	20 (31.75)	35 (28.69)
	Other	1 (1.69)	0 (0)	1 (0.82)
Fur color	White	37 (62.71)	36 (57.14)	73 (59.84)
	Yellow	22 (37.29)	26 (41.27)	48 (39.34)
	Grey	0 (0)	1 (1.59)	1 (0.82)
Pulse	Float	48 (81.36)	42 (66.67)	90 (73.77)
	Deep	10 (16.95)	9 (14.29)	19 (15.57)
	Rapid	38 (64.41)	30 (47.62)	68 (55.74)
	Smooth	15 (25.42)	23 (41.27)	38 (31.15)
	Thready	7 (11.86)	9 (14.29)	16 (13.11)
	Other	13 (22.03)	18 (28.57)	31 (25.41)

Visit symptom		TRQC (n = 59)	Oseltamivir (n = 63)	Total (n = 122)
Fever	37.4-38 ℃	15 (25.42)	14 (22.22)	29 (23.78)
	38-39 ℃	31 (52.54)	40 (63.49)	71 (58.20)
	39-40 ℃	13 (22.03)	9 (14.29)	22 (18.03)
Aversion to cold		42 (71.19)	44 (69.84)	86 (70.49)
Sweating		19 (32.20)	26 (41.27)	45 (36.89)
Cough		44 (74.58)	51 (80.10)	95 (77.87)
	Mild	17 (28.81)	21 (33.33)	38 (31.15)
	Moderate	22 (37.29)	27 (42.86)	49 (40.16)
	Severe	5 (8.47)	3 (4.76)	8 (6.56)
Expectoration	Non	25 (42.37)	29 (46.03)	54 (44.26)
	less	29 (49.15)	28 (44.44)	57 (46.72)
	Much	5 (8.47)	6 (9.52)	11 (9.02)
	White	23 (39.00)	21 (33.33)	44 (36.06)
	Yellow	11 (18.64)	13 (20.63)	24 (19.67)
	Viscous	18 (30.51)	24 (38.10)	42 (24.43)
	Clear	16 (27.12)	10 (15.87)	26 (21.31)
Runny nose		29 (49.15)	29 (46.03)	58 (47.54)
	Clear	24 (40.68)	23 (36.51)	47 (38.52)
	Yellow	5 (8.47)	6 (9.52)	11 (9.02)
Nasal obstruction Obstruction		21 (25.59)	35 (55.56)	56 (45.90)
Sore throat		44 (74.58)	41 (65.08)	85 (69.67)
	Mild	20 (33.90)	16 (25.40)	36 (29.51)
	Moderate	19 (32.20)	22 (34.92)	41 (33.61)
	Severe	5 (8.47)	3 (4.76)	8 (6.56)
Dry mouth		30 (50.85)	31 (49.21)	61 (50.00)
Myalgia		37 (62.71)	43 (68.25)	80 (65.57)
	Mild	16 (27.12)	18 (28.57)	34 (27.87)
	Moderate	14 (23.73)	16 (25.40)	30 (24.59)
	Severe	7 (11.86)	9 (14.29)	16 (13.11)
Headache		44 (74.58)	53 (84.13)	95 (79.51)
	Mild	24 (40.68)	22 (34.92)	34 (27.87)
	Moderate	14 (23.73)	23 (36.51)	30 (24.59)
	Severe	6 (10.17)	8 (12.70)	16 (13.11)
Chest pain		13 (22.03)	10 (15.87)	23 (18.85)
Fatigue		46 (77.97)	49 (77.78)	95 (77.87)
Insomnia		8 (13.56)	9 (14.29)	17 (13.93)
Constipation		9 (15.25)	6 (9.52)	15 (12.30)
Ungratifying defecation		1 (1.69)	5 (7.94)	6 (4.92)
Loose stool		6 (10.17)	4 (6.35)	15 (12.30)
Anorexia		26 (44.07)	28 (44.44)	54 (44.26)
Vomit		8 (13.56)	3 (4.76)	11 (9.02)
Yellow urine		23 (39.00)	24 (38.10)	47 (38.52)
Clear urine		31 (52.54)	30 (47.62)	61 (50.00)
Tongue shape	Old	6 (10.17)	3 (4.76)	9 (7.38)
	Tender	21 (35.59)	22 (34.82)	43 (35.25)
	Bulky	15 (25.42)	17 (27.00)	32 (26.23)
	Thin	10 (16.95)	9 (14.29)	19 (15.57)
	Crack	4 (6.78)	10 (15.87)	14 (11.48)
	Others	3 (5.08)	2 (3.17)	5 (4.10)
Tongue color	Pale white	12 (20.33)	15 (23.81)	27 (22.13)
	Light red	23 (38.98)	31 (49.21)	54 (44.26)
	Red	24 (40.68)	17 (26.98)	41 (33.61)
Tongue coating	Thick	14 (23.73)	13 (20.63)	27 (22.13)
	Thin	25 (42.37)	27 (42.86)	52 (42.62)
	moist	2 (3.39)	2 (3.17)	4 (3.28)
	dryness	2 (3.39)	1 (1.59)	3 (2.46)
	Greasy	15 (25.42)	20 (31.75)	35 (28.69)
	Other	1 (1.69)	0 (0)	1 (0.82)
Fur color	White	37 (62.71)	36 (57.14)	73 (59.84)
	Yellow	22 (37.29)	26 (41.27)	48 (39.34)
	Grey	0 (0)	1 (1.59)	1 (0.82)
Pulse	Float	48 (81.36)	42 (66.67)	90 (73.77)
	Deep	10 (16.95)	9 (14.29)	19 (15.57)
	Rapid	38 (64.41)	30 (47.62)	68 (55.74)
	Smooth	15 (25.42)	23 (41.27)	38 (31.15)
	Thready	7 (11.86)	9 (14.29)	16 (13.11)
	Other	13 (22.03)	18 (28.57)	31 (25.41)

Syndrome type	TRQC (n = 59)	Oseltamivir (n = 63)	Total (n = 122)
External wind-cold	19 (32.20)	16 (25.40)	35 (28.69)
External wind- heat	28 (47.46)	27 (42.85)	55 (45.08)
Phlegm heat obstructs the lung	4 (6.78)	10 (15.87)	14 (11.48)
Phlegm dampness accumulation in the lung	2 (3.39)	3 (4.76)	5 (4.10)
Other types	6 (10.17)	7 (11.11)	13 (10.66)

Home

Online First

Author Center

Reviewer Center

Issues

Announcement

About Us

A multicenter, randomized, double-blind, double-dummy, positive-controlled study of the general treatment method using Tanreqing capsule (痰热清胶囊) in uncomplicated influenza

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 7

References 24

Related Articles 15

Recommended Articles

Metrics

Comments

Item	TRQC (n = 59)	Oseltamivir (n = 63)
Flu symptom relief time (h)	73.1±35.2	75.2±31.4
Fever relief time (h)	30.4±20.8	37.8±25.3
Cough relief time (h)	33.6±38.2	43.7±42.5
Sore throat relief time (h)	53.3±35.5	59.1±34.3
Nasal congestion relief time (h)	25.6±36.0	21.8±35.4
Myalgia relief time (h)	41.6±30.6	39.6±27.0
Headache relief time (h)	53.1±34.8	60.5±29.9
Fatigue relieve time (h)	42.4±28.8	42.3±24.5
Antifebrile using case [n (%)]	1 (1.7)	6 (9.5)
Antibiotic using case [n (%)]	2 (3.4)	4 (6.4)

Time	Group	Fever	Cough	Nasal obstruction	Sore throat	Myalgia	Headache	Fatigue	Total score
1 d	TRQC (n = 59)	2.23±0.73	1.08±1.04	1.08±1.03	1.15±1.14	1.85±0.90	1.31±0.75	1.92±0.64	10.61±3.71
	Oseltamivir (n = 63)	2.17±0.79	1.44±0.86	0.56±0.86	1.33±1.08	1.94±0.87	1.94±0.94	2.06±0.80	11.44±4.08
2 d	TRQC (n = 59)	1.55±0.74	1.55±0.94	0.84±0.87	1.43±0.94	1.35±0.88	1.41±0.79	1.57±0.79	9.69±3.57
	Oseltamivir (n = 63)	1.48±0.78	1.60±0.80	0.73±0.82	1.48±0.90	1.40±0.85	1.33±0.83	1.54±0.80	9.56±3.40
3 d	TRQC (n = 59)	1.22±0.85	1.087±1.00	0.91±1.08	0.96±1.02	1.17±1.11	1.22±1.00	1.43±0.90	8.00±4.49
	Oseltamivir (n = 63)	1.03±0.85	1.33±0.82	0.67±0.92	1.00±0.90	1.18±0.92	1.00±0.87	1.39±0.86	7.61±3.90
4 d	TRQC (n = 59)	0.61±0.78	1.17±0.94	0.78±0.95	0.91±1.08	0.96±1.02	0.83±0.98	1.22±0.95	6.48±5.04
	Oseltamivir (n = 63)	0.70±0.77	1.15±0.83	0.55±0.79	0.73±0.84	0.67±0.69	0.82±0.81	1.12±0.78	5.73±3.69
5 d	TRQC (n = 59)	0.30±0.56	1.04±0.88	0.61±0.84	0.78±1.00	0.43±0.66	0.48±0.67	1.00±0.85	4.65±4.24
	Oseltamivir (n = 63)	0.45±0.57	0.87±0.81	0.39±0.62	0.45±0.77	0.29±0.53	0.42±0.72	0.65±0.66	3.51±3.46

Time	TRQC (n = 59)	Oseltamivir (n = 63)	P value
Fever for 3 or more days	5 (8.47)	10 (15.87)	0.28
Fever less than 1 d	43 (72.88)	32 (50.80)	0.02

[1]	ZHENG Haizhen, CHEN Baohao, ZOU Hanlin, LI Yingjie, WU Wenzhe, HUANG Guomin. Efficacy and safety of moxibustion therapy for bronchial asthma: a systematic review and network Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2026, 46(5): 1047-1060.
[2]	LIU Na, CHEN Zhimin, ZHAO Gang, YUAN Bin, HUANG Zhijun, ZHANG Xuerong, SONG Guihua, CHEN Huafang. Efficacy and safety of the Chinese herbal medicine Xiao’er Niuhuang antipyretic plaster (小儿牛黄退热贴膏) for treating fever in children with acute upper respiratory tract infection with wind-heat syndrome: a multicenter, randomized, double-blind, controlled clinical trial [J]. Journal of Traditional Chinese Medicine, 2026, 46(3): 666-673.
[3]	WANG Xin, CAO Xue, QIN Yuning, SUN Minglin, YUE Lihong, TIAN Yukun, WANG Guangjun, LIU Xinglong, WANG Zirong, Labasangzhu , LIU Jia. Effect of electro-thumbtack needles on symptoms during high-altitude exposure: a pilot, single-blind, randomized, controlled study [J]. Journal of Traditional Chinese Medicine, 2026, 46(3): 674-683.
[4]	HU Wenyue, ZHONG Biying, WANG Zhenyi, ZHANG Meng, CHANG Ze, TAN Xi, HAN Zhenyun. Efficacy of Traditional Chinese Medicine psychosomatic integration therapy for subthreshold depression: a multicenter randomized controlled trial [J]. Journal of Traditional Chinese Medicine, 2026, 46(2): 392-400.
[5]	LI Shuning, LIU Hongxu, LAI Xiaolei, SHANG Juju, XING Wenlong, ZHANG Heyi. Efficacy and safety of Yi’anning pills (益安宁丸) for stable angina pectoris in coronary heart disease with Qi-blood and liver-kidney deficiency syndrome: a multicenter, randomized, double-blind, superiority clinical trial [J]. Journal of Traditional Chinese Medicine, 2026, 46(2): 401-410.
[6]	XU Huanfang, LI Jiashan, YANG Li, WU Wenzhong, YANG Jun, ZHANG Wei, LI Hui, QU Nini, WANG Rui, WANG Landi, YANG Hongzhi, ZHANG Lihua, HE Yong, XIONG Guanyu, LIU Baoyan, FANG Yigong. Effect of point application therapy for bronchial asthma: a multicenter randomized controlled trial [J]. Journal of Traditional Chinese Medicine, 2026, 46(1): 195-204.
[7]	YUAN Menghua, SHAO Jianbin, YANG Yawei, ZHAO Yan, HU Xingang. Combined acupuncture and herb treatment improves intestinal flora inabdominally obese subjects based on 16s rRNA sequencing: a randomized controlled trial [J]. Journal of Traditional Chinese Medicine, 2026, 46(1): 205-210.
[8]	LI Jiansheng, WANG Haifeng, ZHANG Kang, XIE Kai, LI Suyun, ZHANG Chenxi, ZHANG Yaqing. Traditional Chinese Medicine treatment with syndrome differentiation for patients with severe community-acquired pneumonia: a multicenter, randomized, placebo-controlled trial [J]. Journal of Traditional Chinese Medicine, 2025, 45(6): 1376-1384.
[9]	ZHANG Yibao, CHEN Feng, SUN Meng, WANG Zhenwei, TANG Binqing, QIAN Yechang, JIA Wei, BAO Yufang, LI Wenjie, LI Shanqun, ZHANG Wei. Dongtian Changchun ointment (洞天长春膏) for moderate-to-severe chronic obstructive pulmonary disease: a multicenter, prospective, open-label, randomized controlled trial [J]. Journal of Traditional Chinese Medicine, 2025, 45(6): 1395-1404.
[10]	ZHANG Xiaosi, ZHANG Shuangyuan, CHEN Hanqing, LIN Zhengdao, XIE Chune, LI Junxiang, LI Xiaohong. Hewei Jiangni recipe (和胃降逆方) improved the quality of life in patients with cold-heat mixed nonerosive reflux disease: a randomized, double-blinded study [J]. Journal of Traditional Chinese Medicine, 2025, 45(5): 1106-1118.
[11]	HAO Shulan, NAN Peng, LIU Likun, LI Xiaoli, ZHONG Qiming, GAO Yu, WANG Xixing, NIE Yingfang. Effectiveness of Yiqi Chupi powder (益气除疲散) for alleviating cancer-related fatigue in patients following colorectal cancer surgery: a randomized controlled trial [J]. Journal of Traditional Chinese Medicine, 2025, 45(5): 1119-1126.
[12]	GUO Jixing, JI Changchun, XIE Chaoju, RAO Xiang, SUN Zhangyin, XING Yu, ZHANG Rongni, QU Qiangqiang, DONG Youpeng, YANG Jinsheng. Various acupuncture therapies for managing nonspecific low back pain: a network Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2025, 45(5): 954-962.
[13]	CHEN Ziying, ZHAO Xiaoping, FAN Xiaoxuan, TANG Didi, SUN Wen, LYU Jing, HUANG Lan, QI Fan. Seven Traditional Chinese Medicine external treatments combined with rehabilitation training on the functional recovery of limbs in patients with cerebral hemorrhage: a network Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2025, 45(4): 711-719.
[14]	ZHAO Weibo, WANG Yaqi, KONG Lingyao, WANG Tianyi, ZHAO Haihong, ZHANG Ying, LUO Bin, WANG Ji, WANG Qi. Efficacy and safety of Tuomin Zhiti decoction (脱敏止嚏汤) on patients with seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial [J]. Journal of Traditional Chinese Medicine, 2025, 45(4): 829-835.
[15]	LI Yuxuan, LI Yan, WANG Wujiao, CUI Xiaoyun, WAN Jie, ZHOU Kun, LU Jinjin, LIU Jing, LIN Qian, LI Dong. Clinical study of Yiqi Liangxue Shengji prescription (益气凉血生肌方) for improving cardiac function after myocardial ischemia reperfusion injury in patients with acute myocardial infarction: a randomized, double-blind, placebo-controlled trial [J]. Journal of Traditional Chinese Medicine, 2025, 45(4): 836-844.